Explore the Role of the Sphingosine-1-Phosphate Signalling as a Novel Promising Therapeutic Target for the Management of Parkinson's Disease

被引:0
|
作者
Bisht, Manoj [1 ]
Kadian, Jai Parkash [2 ]
Akhilesh [3 ]
Hooda, Tanuj [4 ]
Jain, Neelam [5 ]
Lather, Amit [4 ]
Aggarwal, Navidha [4 ]
机构
[1] Devasthali Vidyapeeth Coll Pharm, Rudrapur, Uttarakhand, India
[2] Shobhit Univ, Adarsh Vijendra Inst Pharmaceut Sci, Saharanpur, UP, India
[3] IIT BHU, Dept Pharmaceut Engn & Technol, Varanasi, UP, India
[4] Maharishi Markandeshwar Deemed Univ, MM Coll Pharm, Mullana Ambala 133207, Haryana, India
[5] Bhagat Phool Singh Mahila Vishwavidyalaya, Dept Pharmaceut Educ & Res, Sonepat, Haryana, India
关键词
central nervous system; neuroinflammation; neuroprotective; Parkinson's disease; sphingosine 1-phosphate (S1P) signalling; CENTRAL-NERVOUS-SYSTEM; SPHINGOSINE KINASE; NONMOTOR SYMPTOMS; MOUSE MODEL; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ALPHA-SYNUCLEIN; CERAMIDE; FINGOLIMOD; DIAGNOSIS;
D O I
10.1055/a-2401-4578
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Sphingosine-1-phosphate (S1P) is a cellular signalling molecule derived from sphingosine, which is a pro-apoptotic sphingolipid. Sphingolipids control various cellular actions like growth, homeostasis, and stress-related responses. The main sources of S1P in our body are erythrocytes. S1P controls both cellular mediators and other second messengers intracellularly. The S1P receptor also helps in inflammatory and neuroprotective effects (required to manage of Parkinson's). A large number of anti-Parkinson drugs are available, but still, there is a need for more effective and safer drugs. S1P and its receptors could be targeted as novel drugs due to their involvement in neuro-inflammation and Parkinson's. The present review effort to explore the biological role of S1P and related receptors, for their possible involvement in PD; furthermore. Overall, S1P and other related metabolizing enzymes have significant therapeutic opportunities for Parkinson's disease along with other neurological disorders.
引用
收藏
页码:365 / 378
页数:14
相关论文
共 50 条
  • [31] Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target
    Di Paolo, Alice
    Vignini, Arianna
    Alia, Sonila
    Membrino, Valentina
    Delli Carpini, Giovanni
    Giannella, Luca
    Ciavattini, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [32] Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease
    Jung, Younghun
    Lopez-Benitez, Jonathan
    Tognoni, Christina M.
    Carreras, Isabel
    Dedeoglu, Alpaslan
    BRAIN RESEARCH, 2023, 1799
  • [33] S1 pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer
    Degagne, Emilie
    Saba, Julie D.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 205 - 214
  • [34] Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation
    Hsing-Chuan Tsai
    May H. Han
    Drugs, 2016, 76 : 1067 - 1079
  • [35] The Critical Role of SIRT1 in Parkinson's Disease: Mechanism and Therapeutic Considerations
    Li, Xuan
    Feng, Ya
    Wang, Xi-Xi
    Truong, Daniel
    Wu, Yun-Cheng
    AGING AND DISEASE, 2020, 11 (06): : 1608 - 1622
  • [36] HMGB1 is a Potential and Challenging Therapeutic Target for Parkinson’s Disease
    Yu Tian
    Rong Chen
    Zhaoliang Su
    Cellular and Molecular Neurobiology, 2023, 43 : 47 - 58
  • [37] Circadian system A novel diagnostic and therapeutic target in Parkinson's disease?
    Videnovic, Aleksandar
    Willis, Gregory L.
    MOVEMENT DISORDERS, 2016, 31 (03) : 260 - 269
  • [38] High Mobility Group Box 1 Protein: A Plausible Therapeutic Molecular Target in Parkinson's Disease
    Goyal, Ahsas
    Agrawal, Anant
    Dubey, Nandini
    Verma, Aanchal
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2024, 25 (08) : 937 - 943
  • [39] PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
    Zheng, Bin
    Liao, Zhixiang
    Locascio, Joseph J.
    Lesniak, Kristen A.
    Roderick, Sarah S.
    Watt, Marla L.
    Eklund, Aron C.
    Zhang-James, Yanli
    Kim, Peter D.
    Hauser, Michael A.
    Gruenblatt, Edna
    Moran, Linda B.
    Mandel, Silvia A.
    Riederer, Peter
    Miller, Renee M.
    Federoff, Howard J.
    Wuellner, Ullrich
    Papapetropoulos, Spyridon
    Youdim, Moussa B.
    Cantuti-Castelvetri, Ippolita
    Young, Anne B.
    Vance, Jeffery M.
    Davis, Richard L.
    Hedreen, John C.
    Adler, Charles H.
    Beach, Thomas G.
    Graeber, Manuel B.
    Middleton, Frank A.
    Rochet, Jean-Christophe
    Scherzer, Clemens R.
    SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (52)
  • [40] GPX3 as a Novel and Potential Therapeutic Target in the Shared Molecular Mechanisms of Traumatic Brain and Parkinson's Disease
    Wang, Yue
    Fang, Jiang
    Yuan, Qiang
    Yu, Jian
    Hu, Jin
    JOURNAL OF INFLAMMATION RESEARCH, 2025, 18 : 1911 - 1928